[Investigation of Streptococcus pneumoniae and Haemophilus influenzae isolated from pediatric outpatients nationwide with a respiratory tract infection at the first consultation (2002-2003)--proportion of resistant strains and sensitivity to oral antibacterial agents].
The propotions of resistant strains and sensitivity to oral antibacterial agents were determined for 468 strains of Streptococcus pneumoniae and 557 strains of Haemophilus influenzae isolated from pediatric outpatients with a respiratory tract infection at the first consultation at 20 medical institutions nationwide in the predefined 4-week period during November 2002 and June 2003. PRSP of the S. pneumoniae strains, accounted for 27%, and BLNAR accounted for 35% of the H. influenzae strains. Against the S. pneumoniae strains, faropenem showed the best MIC90 value, 0.5 microg/mL, of the beta-lactam antibacterial agents, followed by cefditoren-pivoxil, and among the macrolide and ketolide antibacterial agents, telithromycin showed the best MIC90 value, 0.12 microg/mL. Against the H. influenzae strains, cefditoren-pivoxil showed the best MIC90 value, 0.25 microg/mL, among the beta-lactam antibacterial agents, and among the macrolide and ketolide antibacterial agents, azithromycin showed the best activity, followed by telithromycin. It seems necessary to take these results into consideration when choosing drugs for treatment. It will be necessary to survey the trends in resistant strains and the clinical efficacy of various oral antibacterial agents in the future.
Sunakawa
Keisuke
K
Department of Infection, School of Medicine, Kitasato University.
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D005260:Female; D006192:Haemophilus Infections / Q000382:microbiology; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011008:Pneumococcal Infections / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents